Healthcare
Novo Nordisk’s CagriSema Trial Results Shake Market Confidence
Disappointing Data Spurs $125 Billion Market Value Drop Novo Nordisk’s (NVO) ambitions in the competitive obesity drug market took a...
MIRA Pharmaceuticals Advances Ketamir-2: A Safe Step Forward in Neuropathic Pain Treatment
Favorable safety results pave the way for Phase 1 human trials in early 2025, offering hope for millions seeking non-addictive...
Telomir Pharmaceuticals Unveils Groundbreaking Results in Age-Reversal Science with Telomir-1
Preclinical Study Highlights Significant Longevity Benefits, Sets Stage for Human Trials Telomir Pharmaceuticals (Nasdaq: TELO) has announced groundbreaking preclinical results...
Cigna Ends Speculation Over Humana Merger, Citing M&A Strategy and Financial Criteria
Health insurer clarifies position amid investor interest following Trump’s re-election and merger hopes Cigna Group (CI) has officially stated it...
BioMarin Pharmaceuticals’ New Strategy Promises Strong Upside, Led by Voxzogo and Roctavian
Wedbush Sees Favorable Risk/Reward as BioMarin Targets Growth in Rare Disease Market BioMarin Pharmaceuticals (BMRN), a leader in rare disease...
Viking Therapeutics’ VK2735 Demonstrates Promising Weight Loss Results in Phase 1 and Phase 2 Trials
Clinical Data from Oral and Subcutaneous Doses Show Effective Weight Loss and Support Potential for Long-Term Dosing Strategies Viking Therapeutics...
Merck Posts Q3 Earnings Beat on Keytruda Sales Despite Gardasil Struggles in China
Strong Growth in Keytruda Revenue Contrasts with Decline in Gardasil Sales in China Amid Economic and Regulatory Challenges Merck &...
Tharimmune Advances TH104 Clinical Program for Pruritus in PBC With EMA Guidance
Positive EMA Feedback Boosts Momentum for Tharimmune’s Phase 2 Trial in Treating Debilitating Itch Condition in Primary Biliary Cholangitis Tharimmune...
Apogee Therapeutics’ APG777 Demonstrates Promising Longevity in Phase 1 Study, Ahead of Key 2025 Milestones
Nine-Month Follow-Up Data Validates APG777's Extended Half-Life and Safety, as Investors Look to Pipeline Updates and Upcoming Clinical Data In...
Intuitive Surgical Q3 2024 Earnings: Robust Growth Amid Market Challenges
Key Factors to Watch as da Vinci V Expansion Continues Intuitive Surgical (ISRG) has reported strong third-quarter financial results for...
